Age: 15.0
Sex: U
Vaccine: MMR, VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: No adverse event; Vaccine administerd after multiple temperature excursion; Varivax and MMR II administered on 18-DEC-2024 and an additional dose os MMR II was administered on 17-JAN-2024; Vaccine administerd after multiple temperature excursion; This spontaneous report was received from a nurse practitioner referring to a 15-year-old patient (gender unknown).  No information was provided regarding the patient's medical history, concurrent conditions, drug reactions or allergies, or concomitant medications.  On 19-OCT-2023, administered doses of varicella virus vaccine live (oka/merck) (VARIVAX) and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) were exposed to the temperature excursion of 49.5 degrees Fahrenheit for 2 minutes (refrigerated vaccines); and total time in the range from -14 to -10 degrees Celsius for 27 minutes. On 04-DEC-2023, administered doses of varicella virus vaccine live (oka/merck) (VARIVAX) and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) were exposed to the temperature excursion at total time in the range from -14 to -10 degrees Celsius for 28 minutes. On 06-DEC-2023, administered doses of varicella virus vaccine live (oka/merck) (VARIVAX) and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) were exposed to the temperature excursion at total time in the range from -14 to -10 degrees Celsius for 15 minutes. On 17-DEC-2023, the patient was vaccinated with a dose of varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, lot #X012267, expiration date: 30-APR-2025, administered subcutaneously for prophylaxis (strength was not provided); and  measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection (rHA), lot #W031980, expiration date: 06-OCT-2024, administered intramuscularly for prophylaxis (strength was not provided) that underwent in a temperature excursion. On 10-JAN-2024, administered doses of vaccines were exposed to the temperature excursion at total time in the range from -14 to -10 degrees Celsius for 24 minutes. On 17-JAN-2024, the patient was vaccinated with a dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection (rHA), lot #W031980, expiration date: 06-OCT-2024, administered intramuscularly for prophylaxis (strength was not provided) that underwent in a temperature excursion. The temperature excursion occurred because of a reading from the Digital Data Logger in the vaccines' storage in clinical practice. There was no adverse event. It was noted that the vaccines were reported as right to use.  This is one of several reports from the same reporter.; Sender's Comments:  US-009507513-2401USA016206: US-009507513-2403USA005243: US-009507513-2403USA005252: US-009507513-2403USA005253: US-009507513-2403USA005254: US-009507513-2403USA005255: US-009507513-2403USA005256: US-009507513-2403USA005257: US-009507513-2403USA005258: US-009507513-2403USA005259: US-009507513-2403USA005260: US-009507513-2403USA005261: US-009507513-2403USA005262: US-009507513-2403USA005264: US-009507513-2403USA005265: US-009507513-2403USA005266: US-009507513-2403USA005267: US-009507513-2403USA005268: US-009507513-2403USA005269: US-009507513-2403USA005270: